ROIV
Roivant Sciences Ltd.
Price Chart
Latest Quote
$31.43
+0.23 (+0.74%)
Current Price
| Previous Close | $31.20 |
| Open | $31.90 |
| Day High | $32.11 |
| Day Low | $30.58 |
| Volume | 8,263,245 |
Stock Information
| Shares Outstanding | 719.27M |
| Total Debt | $107.44M |
| Cash Equivalents | $4.29B |
| Revenue | $8.26M |
| Net Income | $-299.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.61B |
| EPS (TTM) | $-0.54 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $19.19B |
| Sales | $8.26M |
| Income | $-299.77M |
| Book/sh | $6.02 |
| Cash/sh | $5.97 |
| Employees | 721 |
Financial Ratios
| Quick Ratio | 18.00 |
| Current Ratio | 18.37 |
| Debt/Eq | 2.03 |
Returns & Margins
| ROA | -14.35% |
| ROE | -7.59% |
| Operating Margin | -14675.08% |
Ownership
| Insider Ownership | 23.39% |
| Institutional Ownership | 75.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -20.16 |
| P/S | 2736.89 |
| P/B | 5.22 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $39.04 |
Technical Indicators
| SMA20 | $29.64 |
| SMA50 | $29.13 |
| SMA200 | $23.56 |
| RSI | 58.67 |
| ATR | 0.9965 |
| Shares Float | 545.51M |
| Short Float | 6.64% |
| Short Ratio | 5.51 |
| Volatility | 1.14 |
| Rel Volume | 1.46 |
Performance History
| Week | +5.72% |
| Month | +11.41% |
| Quarter | +13.06% |
| 6 Months | +37.01% |
| YTD | +43.32% |
| Year | +182.90% |
| 3 Years | +221.37% |
| 5 Years | +215.56% |
| 10 Years | +202.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $31.43 | 8,263,100 |
| 2026-06-17 | $31.20 | 7,849,200 |
| 2026-06-16 | $30.41 | 3,886,400 |
| 2026-06-15 | $30.03 | 3,993,000 |
| 2026-06-12 | $30.04 | 5,304,900 |
| 2026-06-11 | $29.73 | 4,507,300 |
| 2026-06-10 | $28.41 | 4,268,500 |
| 2026-06-09 | $29.05 | 3,487,600 |
| 2026-06-08 | $28.49 | 6,072,600 |
| 2026-06-05 | $28.58 | 4,643,400 |
| 2026-06-04 | $29.53 | 4,244,400 |
| 2026-06-03 | $28.70 | 3,612,700 |
| 2026-06-02 | $28.25 | 5,069,600 |
| 2026-06-01 | $29.09 | 4,115,100 |
| 2026-05-29 | $29.99 | 7,735,000 |
| 2026-05-28 | $29.88 | 6,292,600 |
| 2026-05-27 | $29.58 | 6,699,400 |
| 2026-05-26 | $29.67 | 7,294,200 |
| 2026-05-22 | $29.96 | 5,873,900 |
| 2026-05-21 | $30.88 | 10,111,800 |
| 2026-05-20 | $32.41 | 17,010,000 |
| 2026-05-19 | $28.21 | 4,132,400 |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjÃļgren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
đ° Latest News
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory
Insider Monkey âĸ 2026-06-17T13:46:06Z
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
Insider Monkey âĸ 2026-06-11T01:00:08Z
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
Insider Monkey âĸ 2026-06-09T17:41:34Z
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum
Simply Wall St. âĸ 2026-05-26T06:10:15Z
TD Cowen Raises its Price Target on Roivant Sciences (ROIV)
Insider Monkey âĸ 2026-05-25T23:48:46Z
Litigation Windfall Driving Roivant Sciencesâ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)
Simply Wall St. âĸ 2026-05-25T21:09:58Z
Roivant (ROIV) Climbs 15% on Swing to Profits
Insider Monkey âĸ 2026-05-21T02:34:08Z
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Barrons.com âĸ 2026-05-20T20:38:00Z
These Two Biotech Stocks Rocketed â And One Just Broke Out
Investor's Business Daily âĸ 2026-05-20T20:11:58Z
Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...
GuruFocus.com âĸ 2026-05-20T19:00:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,285,000 | $911,000 | $1,599,000 | $3,034,000 |
| Cost Of Revenue | $1,285,000 | $911,000 | $1,599,000 | $3,034,000 |
| Total Revenue | $8,260,000 | $29,053,000 | $32,713,000 | $31,530,000 |
| Operating Revenue | $8,260,000 | $29,053,000 | $32,713,000 | $31,530,000 |
| Expenses | ||||
| Total Expenses | $1,293,563,000 | $1,142,734,000 | $857,641,000 | $840,544,000 |
| Other Income Expense | $842,616,000 | $173,716,000 | $5,246,359,000 | $-108,160,000 |
| Other Non Operating Income Expenses | $-43,692,000 | $5,035,000 | $-60,400,000 | $-18,872,000 |
| Net Non Operating Interest Income Expense | $178,109,000 | $258,375,000 | $146,425,000 | $32,184,000 |
| Operating Expense | $1,292,278,000 | $1,141,823,000 | $856,042,000 | $837,510,000 |
| General And Administrative Expense | $610,466,000 | $591,410,000 | $416,133,000 | $383,448,000 |
| Interest Expense | - | - | $34,778,000 | $27,968,000 |
| Interest Expense Non Operating | - | - | $34,778,000 | $27,968,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-299,771,000 | $-545,011,000 | $4,664,073,000 | $-782,639,000 |
| Net Interest Income | $178,109,000 | $258,375,000 | $146,425,000 | $32,184,000 |
| Interest Income | $178,109,000 | $258,375,000 | $146,425,000 | $32,184,000 |
| Normalized Income | $-831,555,800 | $-671,521,750 | $-617,704,644 | $-710,315,720 |
| Net Income From Continuing And Discontinued Operation | $-299,771,000 | $-171,981,000 | $4,348,926,000 | $-1,009,030,000 |
| Total Operating Income As Reported | $-515,068,000 | $-1,003,294,000 | $4,497,032,000 | $-906,763,000 |
| Net Income Common Stockholders | $-299,771,000 | $-171,981,000 | $4,348,926,000 | $-1,009,030,000 |
| Net Income | $-299,771,000 | $-171,981,000 | $4,348,926,000 | $-1,009,030,000 |
| Net Income Including Noncontrolling Interests | $-397,907,000 | $-356,734,000 | $4,231,206,000 | $-1,115,463,000 |
| Net Income Discontinuous Operations | $0 | $373,030,000 | $-315,147,000 | $-226,391,000 |
| Net Income Continuous Operations | $-397,907,000 | $-729,764,000 | $4,546,353,000 | $-889,072,000 |
| Pretax Income | $-264,578,000 | $-681,590,000 | $4,567,856,000 | $-884,990,000 |
| Special Income Charges | $781,262,000 | $113,495,000 | $5,354,732,000 | $-68,473,000 |
| Interest Income Non Operating | $178,109,000 | $258,375,000 | $146,425,000 | $32,184,000 |
| Operating Income | $-1,285,303,000 | $-1,113,681,000 | $-824,928,000 | $-809,014,000 |
| Gross Profit | $6,975,000 | $28,142,000 | $31,114,000 | $28,496,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.54 | $-0.24 | $5.23 | $-1.42 |
| Basic EPS | $-0.43 | $-0.24 | $5.23 | $-1.42 |
| Other | ||||
| Tax Effect Of Unusual Items | $354,523,200 | $42,170,250 | $24,981,356 | $-16,964,720 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,168,263,000 | $-1,268,291,000 | $-6,109,651,000 | $-700,869,000 |
| Total Unusual Items | $886,308,000 | $168,681,000 | $5,306,759,000 | $-89,288,000 |
| Total Unusual Items Excluding Goodwill | $886,308,000 | $168,681,000 | $5,306,759,000 | $-89,288,000 |
| Reconciled Depreciation | $3,348,000 | $14,071,000 | $22,036,000 | $18,857,000 |
| EBITDA (Bullshit earnings) | $-1,281,955,000 | $-1,099,610,000 | $-802,892,000 | $-790,157,000 |
| EBIT | $-1,285,303,000 | $-1,113,681,000 | $-824,928,000 | $-809,014,000 |
| Diluted Average Shares | $693,864,530 | $725,395,624 | $831,049,444 | $712,791,115 |
| Basic Average Shares | $693,864,530 | $725,395,624 | $783,248,906 | $712,791,115 |
| Diluted NI Availto Com Stockholders | $-299,771,000 | $-171,981,000 | $4,348,926,000 | $-1,009,030,000 |
| Minority Interests | $98,136,000 | $184,753,000 | $117,720,000 | $106,433,000 |
| Tax Provision | $133,329,000 | $48,174,000 | $21,503,000 | $4,082,000 |
| Gain On Sale Of Business | $11,027,000 | $113,495,000 | $5,381,182,000 | $29,276,000 |
| Other Special Charges | $-770,235,000 | - | $26,450,000 | $97,749,000 |
| Gain On Sale Of Security | $105,046,000 | $55,186,000 | $-47,973,000 | $-20,815,000 |
| Research And Development | $681,812,000 | $550,413,000 | $439,909,000 | $454,062,000 |
| Selling General And Administration | $610,466,000 | $591,410,000 | $416,133,000 | $383,448,000 |
| Other Gand A | $610,466,000 | $591,410,000 | $416,133,000 | $383,448,000 |
| Restructuring And Mergern Acquisition | - | - | $26,450,000 | $97,749,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,012,885,000 |
| Total Assets | $5,708,687,000 | $5,436,940,000 | $7,222,482,000 | $2,389,604,000 |
| Total Non Current Assets | $541,303,000 | $436,876,000 | $490,654,000 | $591,017,000 |
| Other Non Current Assets | $40,916,000 | $32,860,000 | $183,577,000 | $49,482,000 |
| Current Assets | $5,167,384,000 | $5,000,064,000 | $6,731,828,000 | $1,798,587,000 |
| Other Current Assets | $105,316,000 | $113,173,000 | $80,605,000 | $15,531,000 |
| Receivables | $770,235,000 | $0 | $82,813,000 | $37,644,000 |
| Other Receivables | $770,235,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $4,291,833,000 | $4,886,891,000 | $6,494,953,000 | $1,676,813,000 |
| Cash And Cash Equivalents | $1,419,232,000 | $2,715,411,000 | $6,494,953,000 | $1,676,813,000 |
| Cash Equivalents | $1,374,706,000 | $2,621,457,000 | $6,312,288,000 | - |
| Cash Financial | $44,526,000 | $93,954,000 | $182,665,000 | - |
| Assets Held For Sale Current | - | $0 | $156,270,000 | - |
| Goodwill And Other Intangible Assets | - | - | $137,842,000 | $144,881,000 |
| Restricted Cash | - | - | $5,367,000 | $5,011,000 |
| Prepaid Assets | - | - | $55,096,000 | $60,827,000 |
| Inventory | - | - | $35,251,000 | $2,761,000 |
| Taxes Receivable | - | - | $1,827,000 | $2,356,000 |
| Accrued Interest Receivable | - | - | $27,441,000 | $4,909,000 |
| Accounts Receivable | - | - | $53,545,000 | $30,379,000 |
| Debt | ||||
| Total Debt | $107,438,000 | $100,170,000 | $53,986,000 | $481,404,000 |
| Long Term Debt And Capital Lease Obligation | $96,291,000 | $90,328,000 | $45,020,000 | $428,991,000 |
| Current Debt And Capital Lease Obligation | $11,147,000 | $9,842,000 | $8,966,000 | $52,413,000 |
| Long Term Debt | - | - | $430,591,000 | $375,515,000 |
| Current Debt | - | - | $12,000,000 | $40,720,000 |
| Other Current Borrowings | - | - | $12,000,000 | $40,720,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $416,275,000 | $249,742,000 | $773,953,000 | $782,017,000 |
| Total Non Current Liabilities Net Minority Interest | $135,031,000 | $100,331,000 | $507,195,000 | $509,569,000 |
| Other Non Current Liabilities | $70,000 | $10,003,000 | $28,230,000 | $80,578,000 |
| Tradeand Other Payables Non Current | $38,670,000 | $0 | - | - |
| Current Liabilities | $281,244,000 | $149,411,000 | $266,758,000 | $272,448,000 |
| Other Current Liabilities | $583,000 | $1,168,000 | $110,405,000 | $2,090,000 |
| Payables And Accrued Expenses | $182,189,000 | $84,473,000 | $93,329,000 | $132,746,000 |
| Payables | $63,691,000 | $24,107,000 | $23,802,000 | $38,372,000 |
| Total Tax Payable | $45,689,000 | $416,000 | $9,773,000 | $542,000 |
| Income Tax Payable | $45,689,000 | $416,000 | $9,773,000 | $542,000 |
| Accounts Payable | $18,002,000 | $23,691,000 | $14,029,000 | $37,830,000 |
| Liabilities Heldfor Sale Non Current | - | $0 | $433,945,000 | - |
| Current Deferred Liabilities | - | $1,168,000 | $4,168,000 | $12,444,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,157,766,000 |
| Total Equity Gross Minority Interest | $5,292,412,000 | $5,187,198,000 | $6,448,529,000 | $1,607,587,000 |
| Stockholders Equity | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,157,766,000 |
| Gains Losses Not Affecting Retained Earnings | $4,358,000 | $9,438,000 | $-4,083,000 | $-2,617,000 |
| Other Equity Adjustments | $4,358,000 | $9,438,000 | $-4,083,000 | $-2,617,000 |
| Retained Earnings | $-501,814,000 | $116,060,000 | $576,172,000 | $-3,772,754,000 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $720,352,386 | $695,938,323 | $806,677,954 | $760,143,393 |
| Share Issued | $720,352,386 | $695,938,323 | $806,677,954 | $760,143,393 |
| Tangible Book Value | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,012,885,000 |
| Invested Capital | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,574,001,000 |
| Working Capital | $4,886,140,000 | $4,850,653,000 | $6,465,070,000 | $1,526,139,000 |
| Capital Lease Obligations | $107,438,000 | $100,170,000 | $53,986,000 | $65,169,000 |
| Total Capitalization | $4,527,370,000 | $4,687,605,000 | $5,968,581,000 | $1,533,281,000 |
| Minority Interest | $765,042,000 | $499,593,000 | $479,948,000 | $449,821,000 |
| Additional Paid In Capital | $5,024,826,000 | $4,562,107,000 | $5,396,492,000 | $4,933,137,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $96,291,000 | $90,328,000 | $45,020,000 | $53,476,000 |
| Current Capital Lease Obligation | $11,147,000 | $9,842,000 | $8,966,000 | $11,693,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $87,325,000 | $53,928,000 | $49,890,000 | $55,186,000 |
| Current Accrued Expenses | $118,498,000 | $60,366,000 | $69,527,000 | $94,374,000 |
| Investments And Advances | $407,985,000 | $302,939,000 | $247,753,000 | $304,317,000 |
| Other Investments | $407,985,000 | $302,939,000 | $247,753,000 | $304,317,000 |
| Net PPE | $92,402,000 | $101,077,000 | $59,324,000 | $92,337,000 |
| Gross PPE | $92,402,000 | $101,077,000 | $59,324,000 | $92,337,000 |
| Other Properties | $92,402,000 | $101,077,000 | $59,324,000 | $92,337,000 |
| Other Short Term Investments | $2,872,601,000 | $2,171,480,000 | $0 | - |
| Current Deferred Revenue | - | $1,168,000 | $4,168,000 | $12,444,000 |
| Current Provisions | - | - | $23,277,000 | $17,569,000 |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-758,558,000 | $-844,050,000 | $-766,650,000 | $-856,083,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-750,349,000 | $-839,451,000 | $-765,268,000 | $-843,393,000 |
| Cash Flow From Continuing Operating Activities | $-750,349,000 | $-839,451,000 | $-765,268,000 | $-843,393,000 |
| Operating Gains Losses | $-12,003,000 | $-481,153,000 | $-5,381,182,000 | $-29,276,000 |
| Investing Activities | ||||
| Capital Expenditure | $-8,209,000 | $-4,599,000 | $-1,382,000 | $-12,690,000 |
| Investing Cash Flow | $-682,333,000 | $-1,766,291,000 | $5,203,623,000 | $-44,269,000 |
| Cash Flow From Continuing Investing Activities | $-682,333,000 | $-1,766,291,000 | $5,203,623,000 | $-44,269,000 |
| Net Other Investing Changes | $-2,518,000 | $110,466,000 | $5,241,988,000 | $-139,434,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-319,503,000 | $-1,293,232,000 | $0 | $0 |
| Issuance Of Capital Stock | $193,605,000 | $112,782,000 | $438,555,000 | $379,708,000 |
| Financing Cash Flow | $134,236,000 | $-1,219,794,000 | $419,364,000 | $499,462,000 |
| Cash Flow From Continuing Financing Activities | $134,236,000 | $-1,219,794,000 | $419,364,000 | $499,462,000 |
| Net Other Financing Charges | $-9,371,000 | $-37,216,000 | $-43,715,000 | $-13,131,000 |
| Net Common Stock Issuance | $-125,898,000 | $-1,180,450,000 | $438,555,000 | $379,708,000 |
| Common Stock Issuance | $193,605,000 | $112,782,000 | $438,555,000 | $379,708,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-52,753,000 | $-30,705,000 | $-30,144,000 |
| Interest Paid Supplemental Data | $0 | $5,963,000 | $10,268,000 | $5,303,000 |
| End Cash Position | $1,430,982,000 | $2,725,661,000 | $6,550,450,000 | $1,692,115,000 |
| Beginning Cash Position | $2,725,661,000 | $6,550,450,000 | $1,692,115,000 | $2,074,034,000 |
| Effect Of Exchange Rate Changes | $3,767,000 | $747,000 | $616,000 | $6,281,000 |
| Changes In Cash | $-1,298,446,000 | $-3,825,536,000 | $4,857,719,000 | $-388,200,000 |
| Proceeds From Stock Option Exercised | $269,505,000 | $50,625,000 | $55,229,000 | $3,130,000 |
| Common Stock Payments | $-319,503,000 | $-1,293,232,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-52,753,000 | $-30,705,000 | $129,755,000 |
| Net Long Term Debt Issuance | $0 | $-52,753,000 | $-30,705,000 | $129,755,000 |
| Long Term Debt Payments | $0 | $-52,753,000 | $-30,705,000 | $-30,144,000 |
| Net Investment Purchase And Sale | $-667,188,000 | $-2,101,521,000 | $0 | $0 |
| Sale Of Investment | $4,128,667,000 | $1,960,000,000 | $0 | $0 |
| Purchase Of Investment | $-4,795,855,000 | $-4,061,521,000 | $0 | $0 |
| Net Business Purchase And Sale | $-4,418,000 | $229,363,000 | $-36,983,000 | $107,855,000 |
| Sale Of Business | $0 | $260,586,000 | $47,500,000 | $114,561,000 |
| Purchase Of Business | $-4,418,000 | $-31,223,000 | $-84,483,000 | $-6,706,000 |
| Net PPE Purchase And Sale | $-8,209,000 | $-4,599,000 | $-1,382,000 | $-12,690,000 |
| Purchase Of PPE | $-8,209,000 | $-4,599,000 | $-1,382,000 | $-12,690,000 |
| Change In Working Capital | $-621,796,000 | $-77,046,000 | $19,035,000 | $6,345,000 |
| Change In Other Current Liabilities | $-3,393,000 | $-4,927,000 | $-10,713,000 | $-6,455,000 |
| Change In Other Current Assets | $4,043,000 | $-33,828,000 | $-64,990,000 | $-49,086,000 |
| Change In Payables And Accrued Expense | $147,789,000 | $-38,291,000 | $94,738,000 | $61,886,000 |
| Change In Accrued Expense | $59,326,000 | $-10,070,000 | $62,127,000 | $57,527,000 |
| Change In Interest Payable | $0 | $0 | $21,977,000 | $18,571,000 |
| Change In Payable | $88,463,000 | $-28,221,000 | $32,611,000 | $4,359,000 |
| Change In Account Payable | $3,418,000 | $-18,168,000 | $22,684,000 | $4,359,000 |
| Change In Tax Payable | $85,045,000 | $-10,053,000 | $9,927,000 | - |
| Change In Income Tax Payable | $85,045,000 | $-10,053,000 | $9,927,000 | - |
| Change In Receivables | $-770,235,000 | $0 | $0 | - |
| Other Non Cash Items | $57,808,000 | $-102,473,000 | $96,037,000 | $37,548,000 |
| Stock Based Compensation | $346,165,000 | $289,029,000 | $199,627,000 | $217,781,000 |
| Unrealized Gain Loss On Investment Securities | $-105,046,000 | $-55,186,000 | $47,973,000 | $20,815,000 |
| Asset Impairment Charge | $15,594,000 | $0 | $0 | - |
| Amortization Of Securities | $-36,512,000 | $-69,959,000 | $0 | $0 |
| Depreciation Amortization Depletion | $3,348,000 | $14,071,000 | $22,036,000 | $18,857,000 |
| Depreciation And Amortization | $3,348,000 | $14,071,000 | $22,036,000 | $18,857,000 |
| Gain Loss On Investment Securities | $-976,000 | - | - | - |
| Gain Loss On Sale Of Business | $-11,027,000 | $-379,614,000 | $-32,772,000 | $-29,276,000 |
| Net Income From Continuing Operations | $-397,907,000 | $-356,734,000 | $4,231,206,000 | $-1,115,463,000 |
| Issuance Of Debt | - | $0 | $0 | $159,899,000 |
| Income Tax Paid Supplemental Data | - | $61,910,000 | $12,354,000 | $5,128,000 |
| Long Term Debt Issuance | - | $0 | $0 | $159,899,000 |
| Change In Other Working Capital | - | - | - | $3,304,000 |
| Earnings Losses From Equity Investments | - | - | - | - |
Fetched: 2026-06-19